I Mab Ownership

IMAB Stock  USD 2.11  0.03  1.44%   
I Mab has a total of 81.66 Million outstanding shares. I Mab retains significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2018-03-31
Previous Quarter
187.5 M
Current Value
81.6 M
Avarage Shares Outstanding
81.4 M
Quarterly Volatility
31.9 M
 
Covid
Some institutional investors establish a significant position in stocks such as I Mab in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of I Mab, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.

IMAB Stock Ownership Analysis

About 30.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. I Mab recorded a loss per share of 0.55. The entity had not issued any dividends in recent years. I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people. To learn more about I Mab call XiYong MBA at 240 745 6330 or check out https://www.i-mabbiopharma.com.
Besides selling stocks to institutional investors, I Mab also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different I Mab's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align I Mab's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

I Mab Quarterly Liabilities And Stockholders Equity

208.94 Million

About 11.0% of I Mab are currently held by insiders. Unlike I Mab's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against I Mab's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of I Mab's insider trades

IMAB Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as I Mab is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading I Mab backward and forwards among themselves. I Mab's institutional investor refers to the entity that pools money to purchase I Mab's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Ground Swell Capital, Llc2025-03-31
63.7 K
Millennium Management Llc2025-03-31
61.5 K
Dimensional Fund Advisors, Inc.2025-03-31
58.4 K
Hbk Sorce Advisory Llc2025-03-31
46.1 K
Morgan Stanley - Brokerage Accounts2025-03-31
34.8 K
Barclays Plc2025-03-31
30.4 K
Mariner Wealth Advisors Llc2025-03-31
28.8 K
Geode Capital Management, Llc2025-03-31
22 K
Hrt Financial Llc2025-03-31
16 K
Hillhouse Capital Advisors, Ltd.2025-03-31
M
Sg Americas Securities, Llc2025-03-31
822 K
Note, although I Mab's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.55)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.11)
Return On Equity
(0.20)
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.